Regeneron to discontinue development of Suptavumab for respiratory syncytial virus
Regeneron Pharmaceuticals announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of…
Read More...
Read More...
